Cargando…
Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times
INTRODUCTION: Concerns have been raised about the limited health system capacity for identification of patients who are eligible for a disease‐modifying Alzheimer's treatment (DMT). Blood‐based biomarker (BBBM) tests are a promising tool to improve triaging at the primary care level. We project...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434228/ https://www.ncbi.nlm.nih.gov/pubmed/32832590 http://dx.doi.org/10.1002/dad2.12081 |